Insights into Support Systems for Orphan Drug Development: A Comparative Study
Therapeutic Innovation & Regulatory Science · 2025
DOI: 10.1007/s43441-025-00833-8 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Ye Leng und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. Hauptthemen laut MEDLINE: Orphan Drug Production, Drug Development, Rare Diseases. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program, National Anti-tumour Drug Surveillance System of National Cancer Centre, hinese Academy of Medical Sciences Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Due to great unmet medical needs, orphan drug development is a common issue of high priority for policymakers, industry leaders, researchers and patients worldwide. The establishment of a harmonized support system is the way forward to address the dilemma facing rare diseases (RDs). This study pioneers the proposal of a framework and dimensions of support systems affecting orphan drug development, covering legal (political and legal basis), technical (regulatory guidance and acceleration), motivational (economic incentives and innovation returns) and logistical (fundamental infrastructure) factors. This study, based on the framework, shows that the conditions for orphan drug development above are basically developed in the US, the EU and China. Additionally, China lags behind in terms of economic incentives and fundamental infrastructure. Continuous improvements in pricing and reimbursement, as well as the acceleration of real-world data (RWD) database and biobank repository integration, are expected in China. Based on these findings from the three study regions, action plans with three strategies (national plans and strategies, a patient-centered health system, global governance and collaborations) and eleven actions are suggested for strengthening synergies between initiatives and stakeholders to satisfy the medical needs of RD patients and families. This study can provide a reference not only for orphan drug development in the three study regions but also for all other countries worldwide, especially for those with a late start in addressing RDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
- Clinical Trials Center, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District…
- Bureau of Medical Administration, National Health Commission, Beijing, 100044, People's Republic of China. zhangwenbao@126.com.
Förderung
- National Key Research and Development Program
- National Anti-tumour Drug Surveillance System of National Cancer Centre
- hinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Leng, Y., Tang, Y., Yu, W., Hou, Y., He, H., Han, Y., Huang, H., Zhang, W., & Li, N. (2025). Insights into Support Systems for Orphan Drug Development: A Comparative Study. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00833-8
Vancouver
Leng Y, Tang Y, Yu W, Hou Y, He H, Han Y, et al. Insights into Support Systems for Orphan Drug Development: A Comparative Study. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00833-8
BibTeX
@article{Leng2025,
author = {Leng, Ye and Tang, Yu and Yu, Weijie and Hou, Yiru and He, Hanqing and Han, Yanjie and Huang, Huiyao and Zhang, Wenbao and Li, Ning},
title = {Insights into Support Systems for Orphan Drug Development: A Comparative Study},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
doi = {10.1007/s43441-025-00833-8}
}
EUVIMED